Reach Pharmaceuticals

What Reach Pharmaceuticals does

Reach Pharmaceuticals is an Australian privately-owned pharmaceutical company founded in 2018 and headquartered in Preston, Victoria. It registers, markets, and distributes complex generic medicines and innovative hospital pharmaceuticals to Australian hospitals, clinicians, and patients, with a stated focus on first-to-market products and compassionate supply arrangements that address drug shortages. The portfolio spans oncology (Nelarabine, Thiotepa, Romidepsin, Carboprost, Cyclophosphamide, Cabazitaxel), supportive care (Dexrazoxane, Fosaprepitant, Furosemide, Captopril), and a small consumer metabolics line (L-Carnitine, Potassium Citrate) sold through its own online store. The company has secured three TGA Orphan Drug Designations (Nelarabine, Carboprost, Dexrazoxane) and an extensive S19A shortage-import pipeline running through 2026, alongside a Cipla partnership that sources Isoprenaline for the Australian market.

Name

Reach Pharmaceuticals

Legal name

Reach Pharmaceuticals Pty Ltd

Website

https://reach-pharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Reach Pharmaceuticals is an Australian privately-owned pharmaceutical company that registers, markets, and distributes complex generic and hospital medicines — including orphan-designated oncology products and S19A shortage imports — to Australian hospitals, clinicians, and consumers.

Ownership category

akta.pro rank

Product category

Specialty Hospital Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Food (Health) Supplement Retailers (456191)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Direct-to-Provider / Clinic Buy-and-Bill Distributors (HLAIAJAM)

Keywords

• Complex generic medicines
• Hospital pharmaceuticals
• Oncology injectables
• Drug shortage supply
• Orphan drug designation

Headquarters

HQ city

Preston

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Direct sales of complex generic medicines and therapeutic goods through online store and wholesale distribution to hospitals and healthcare providers in Australia

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Reach Pharmaceuticals manufactures, registers and distributes complex generic injectable medicines for Australian hospitals, with a first-to-market product strategy. Its portfolio includes TGA-approved REACH-branded oncology and supportive-care injectables (e.g. Nelarabine, Thiotepa, Romidepsin, Carboprost, Dexrazoxane, Cyclophosphamide), S19A import products supplied during drug shortages, and a direct-to-consumer Metabolics supplement line (L-Carnitine, Potassium Citrate) sold through its own online store.

Product overview

Reach Pharmaceuticals is an Australian privately-owned pharmaceutical company specializing in complex generic medicines and innovative products with first-to-market advantages. The company operates in the hospital pharmaceuticals space and holds majority market share for products launched to date. The portfolio includes three main categories: (1) Approved products marketed under the REACH brand including oncology medications such as NELARABINE-REACH, THIOTEPA-REACH, ROMIDEPSIN-REACH, CARBOPROST-REACH, DEXRAZOXANE-REACH, and CYCLOPHOSPHAMIDE-REACH; (2) Metabolics brand supplements including L-Carnitine and Potassium Citrate tablets sold through the company's online store; (3) S19A import products supplied during Australian shortages. Products under compassionate supply programs address critical drug shortages in the Australian market. The company manages the entire process from product identification to sales generation and has received Orphan Drug Designation for multiple products including Nelarabine, Carboprost, and Dexrazoxane.

Differentiator

Problem solved

Functional benefit

Brands

• METABOLICS: Product sub-brand for metabolics health supplements including Potassium Citrate 10 and L-Carnitine
• DEXRAZOXANE-REACH
• NELARABINE-REACH
• ROMIDEPSIN-REACH
• THIOTEPA-REACH
• CARBOPROST-REACH
• CYCLOPHOSPHAMIDE-REACH
• FUROSEMIDE-REACH
• CABAZITAXEL MSN
• FOSAPREPITANT MSN

Products and services

• NELARABINE-REACH 250 mg/50 mL solution for injection Antineoplastic agent for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma, marketed to Australian hospitals under the Reach Pharmaceuticals brand.
• THIOTEPA-REACH powder for injection (15 mg and 100 mg) Alkylating agent for injection used in the treatment of various cancers, TGA approved for the Australian hospital market.
• ROMIDEPSIN-REACH 10 mg powder for injection Antineoplastic agent for the treatment of peripheral T-cell lymphoma, supplied to Australian hospitals via all wholesalers.
• CARBOPROST-REACH solution for injection Prostaglandin analogue for injection used for the treatment of postpartum haemorrhage, supplied to Australian hospitals.
• DEXRAZOXANE-REACH for injection (250 mg and 500 mg) Cardioprotective agent used to prevent anthracycline-induced cardiotoxicity, supplied to Australian hospitals in 250 mg and 500 mg strengths.
• CYCLOPHOSPHAMIDE-REACH powder for injection (500 mg and 1000 mg) Alkylating agent for injection used in the treatment of various cancers and as an immunosuppressant, supplied to Australian hospitals.
• FUROSEMIDE-REACH 20 mg/2 mL solution for injection Loop diuretic for injection used in the treatment of oedema and heart failure, supplied to Australian hospitals.
• MSN CABAZITAXEL injection 60 mg/1.5 mL Antineoplastic taxane agent for injection used in the treatment of prostate cancer, supplied to Australian hospitals.
• FOSAPREPITANT MSN 150 mg powder for injection NK1 receptor antagonist for injection used as an antiemetic for chemotherapy-induced nausea and vomiting, supplied to Australian hospitals.
• CIPLA ISOPRENALINE for injection (0.2 mg/mL and 1 mg/5 mL) Synthetic catecholamine for injection used for cardiac emergencies and bronchospasm, distributed in Australia by Reach Pharmaceuticals under licence from Cipla.
• METABOLICS POTASSIUM CITRATE 10 MR tablets 1.08 g Modified-release potassium citrate supplement for metabolic support, 100 tablets per bottle, A$86.00 GST included, sold direct to consumers via the Reach online store.
• METABOLICS L-CARNITINE 500 mg capsules Levocarnitine tartrate supplement (500 mg per capsule, equivalent to 341 mg L-carnitine), 300 capsules per bottle at A$120.00 GST included, sold direct to consumers via the Reach online store for metabolic, cardiovascular and muscle-function support.
• CAPTOPRIL-REACH captopril 5 mg/mL oral solution ACE inhibitor oral solution for the treatment of hypertension and heart failure, supplied to Australian hospitals and patients.
• Icatibant 30 mg/3 mL (Reach hospital supply) Bradykinin B2 receptor antagonist injection for the treatment of hereditary angioedema, supplied to Australian hospitals and PBS-listed.

Quantifiable outcome

• First carboprost formulation launched since innovator brand discontinued in 2013
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• CiplaminorOthers · 1 June 2022Cipla supplies Isoprenaline injection products (0.2mg/mL and 1mg/5mL) that Reach Pharmaceuticals launched in Australia in June 2022. Reach handles local regulatory approvals, marketing, and distribution while sourcing from Cipla's product portfolio.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mayne Pharma Group: Australian-listed specialty pharmaceutical company focused on complex generics and specialty pharmaceuticals, including oncology and women's health products. Highly comparable to Reach's hospital-focused complex generics strategy, though operating at much larger scale across multiple geographies.
• Juno Pharmaceuticals: Australian specialty pharmaceutical company focused on hospital medicines, oncology, and rare disease products. Highly comparable niche focus to Reach, though Juno also distributes through its own hospital sales infrastructure.
• Specialised Therapeutics Australia (ST&A): Australian specialty pharmaceutical company partnering with global manufacturers to bring oncology and specialty medicines to the Australian market. Closely comparable business model to Reach — partnership-led, hospital-focused, complex/limited-population products — and a likely direct competitor for the same supplier partnerships.
• Arrotex Pharmaceuticals: Australia's largest generic pharmaceutical company, marketing a broad generics portfolio through pharmacy and hospital channels. Directly comparable to Reach's S19A shortage-import and complex generic registration model in the Australian market, but at substantially greater scale.
• Cipla Australia: Australian arm of Cipla, India's third-largest pharma company and a major global supplier of complex generics including oncology injectables and respiratory products. Already a supplier-partner to Reach (Isoprenaline), and a potential direct competitor or future acquirer given overlapping portfolios.

Broad incumbents

• Sandoz (Australia): Novartis's global generics division, with a substantial Australian presence across hospital injectables, oncology generics, and complex formulations. Direct category overlap with Reach's hospital pharmaceutical focus, but as part of a worldwide portfolio and significantly greater resources.
• Alphapharm (Viatris): Viatris's Australian generics business, one of the largest suppliers of multisource medicines to Australian hospitals and the PBS. Competes with Reach in the same hospital and PBS channels, but as part of a global generics portfolio spanning thousands of SKUs.
• Apotex (Australia): Canadian-headquartered global generics manufacturer with Australian operations supplying PBS-listed medicines, including hospital injectable generics. Comparable in product categories (complex generics, injectables) but vastly larger and broader portfolio.
• AstraZeneca Australia: Australian subsidiary of AstraZeneca, the originator of several products Reach now supplies as generics (e.g., carboprost, nelarabine). A natural counterparty: Reach's generics either substitute for or, under compassionate supply, complement AstraZeneca's innovator portfolio.

Regional players

• Aspen Pharmacare Australia: Australian arm of South African-headquartered Aspen Pharmacare, focused on specialty branded generics and hospital pharmaceuticals in Australia. Comparable product categories (oncology, injectables) though Aspen's geographic center of gravity is outside Australia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/reach-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reach Pharmaceuticals